News | Cardiovascular Ultrasound | June 15, 2022

Cardiawave Confirms the Safety of VALVOSOFT its Non-Invasive Ultrasound Treatment for Aortic Stenosis

Successful completion of the FIM II clinical study prior to the pivotal study, that will pave the way for CE marking

Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced positive MRI scans before and after therapeutic ultrasound treatment to assess the risk of stroke.

This final phase of the clinical study “Valvosoft FIM STUDY” (FIM II) showed no signs of any cerebral vascular anomaly in the 10 patients treated. This marks the completion of two successful First-In-Human clinical studies involving a total of 40 patients treated in France, the Netherlands and Serbia.

“This confirmation of the safety of Valvosoft bodes well for the launch of patient recruitment for our European pivotal study which will commence shortly in France, and extended to Germany and the Netherlands, with the aim of obtaining CE Marking.” said Benjamin Bertrand, CEO of Cardiawave.

Valvosoft’s non-invasive treatment brings great hope for patients with aortic stenosis and for their families. Having the absence of any abnormality before and after treatment being confirmed by MRI scans is major clinical step forward” declared Professeur Emmanuel Messas the Georges Pompidou European Hospital (AP-HP), in Paris.

For more information: www.cardiawave.com

 


Related Content

News | Cardiac Imaging

November 16, 2023 — Cardiovascular diseases rank among the top causes of death across the world, and cardiac ...

Home November 16, 2023
Home
News | Cardiac Imaging

September 21, 2023 — Declines in cardiovascular procedure volumes observed early in the COVID-19 pandemic greatly ...

Home September 21, 2023
Home
News | Cardiac Imaging

July 11, 2023 — Hyperfine, Inc., the groundbreaking medical device company that created the Swoop system, the world’s ...

Home July 11, 2023
Home
Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

Home July 10, 2023
Home
News | Cardiac Imaging

June 29, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home June 29, 2023
Home
News | Cardiac Imaging

June 26, 2023 — Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited ...

Home June 26, 2023
Home
News | Cardiac Imaging

June 15, 2023 — Dr. Jonathan Weinsaft, an esteemed physician-scientist who focuses on clinical research and ...

Home June 15, 2023
Home
News | Cardiac Imaging

June 9, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

Home June 09, 2023
Home
Feature | Cardiac Imaging | By Mohammad Sahebjalal, MD

Invented in 1896 by Enrico Salvioni, the fluoroscope remains a flagship technology of modern medicine. The live video X ...

Home May 04, 2023
Home
News | Cardiac Imaging

April 26, 2023 — In the majority of cases, graft failure after heart transplantation is attributable to abnormalities ...

Home April 26, 2023
Home
Subscribe Now